Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy Biotech Investing
DelMar Pharmaceuticals Announces Presentation at the European Association of Neuro-Oncology Annual Meeting in October 2016 Life Science Investing
Naturally Splendid Escalates 2016 Growth: New $2.1 Million Purchase Order Shoots Growth Rate to 3000% Since 2015 Biotech Investing
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. Highlighting Recent Uplisting to Nasdaq Life Science Investing
Fera Pharmaceuticals and Oakwood Labs Announce ANDA Approval of Levothyroxine Sodium for Injection Life Science Investing
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
